Intellia Therapeutics
存在感
役員
21人の主要幹部と一緒に組織図を見る
Intellia Therapeuticsでもっとも検索された略歴
- John Leonard, President, Chief Executive Officer and Director
- Bill Chase, Director
- Jesse Goodman, Director
更新履歴 - ％sの
- Independent DirectorのJohn Crowleyは退社しました (2023年12月7日公開されたニュース).
アラートを作成
Intellia Therapeutics のエグゼクティブの異動をフォローします。
バイオテクノロジー
Intellia TherapeuticsはEurofins (ルクセンブルグ大公国),Lonza (スイス連邦),Adaptive Phage Therapeutics (アメリカ合衆国（米国）)を含む2,274の競合企業を有します。
Popular M&A news in バイオテクノロジー
- Bruker has announced the acquisition of NanoString Technologies (2024年4月18日に公開).
- Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences (2024年4月16日に公開).
- ％sは、％s百万ドルの資金調達を発表しました。 (2024年4月13日に公開).
バイオテクノロジー業界でのその他のコンタクトの提案
ニュース
％sによる最新のプレスリリース
- Intellia Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress - Intellia Therapeutics
- Press Releases - Intellia Therapeutics
- Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2022 Earnings and Company Updates - Intellia Therapeutics
- Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single Dose - Intellia Therapeutic
- Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the International Liver Congress™ 2022 - Intellia Therapeutics
- Intellia Therapeutics Announces First Quarter 2022 Financial Results and Highlights Recent Company Progress - Intellia Therapeutics
- Intellia Therapeutics Names Muna Bhanji, R.Ph., to its Board of Directors - Intellia Therapeutics
- Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its CRISPR-Engineered Allogeneic Platform at the 2022 Keystone Symposia’s Precision Genome Engineering Conference - Intellia Therapeutics
- Intellia Therapeutics Receives Authorization to Initiate Phase 1 Clinical Trial of NTLA-2001 for Transthyretin Amyloidosis (ATTR) | Intellia Therapeutics
- Intellia Therapeutics Congratulates Co-Founder Jennifer Doudna On Winning the 2020 Nobel Prize in Chemistry for Inventing the Revolutionary CRISPR/Cas9 Genome Editing Technology | Intellia Therapeutics
- View more press releases Close
％sについてのソーシャルメディア
- Intellia Therapeutics についてのウィキペディア,Google News & Yahoo Financeの記事
- Intellia Therapeutics についてのLinkedIn,ツイッター & YouTubeの記事
